Tuesday, September 17, 2013

New EGFR VIP Summary Published in PG&G

The epidermal growth factor receptor (EGFR) is involved in the growth of many epithelial malignancies, such as non-small-cell lung cancer (NSCLC), pancreatic and colorectal cancer. It has therefore been a key target for the development of cancer therapeutics. These include tyrosine kinase inhibitors (gefinitib and erolinitib) and monoclonal antibodies (cetuximab and panitumumab).
The PharmGKB Very Important Pharmacogene (VIP) Summary for EGFR provides a concise overview of the role of EGFR as a drug target in the treatment of cancer. Key somatic and germline EGFR polymorphisms associated with drug responsiveness and acquired drug resistance are discussed.

Read the publication:
PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor. Hodoglugil U, Carrillo MW, Hebert JM, Karachaliou N, Rosell RC, Altman RB, Klein TE.
Pharmacogenet Genomics. 2013 Aug 18. (Epub ahead of print)